(60 days)
The Stat Profile Prime Plus Analyzer System is intended for use by healthcare professionals in clinical laboratory settings and for point-of-care usage for quantitative determination of pH, Partial Pressure of Carbon Dioxide (pCO2) and Partial Pressure of Oxygen (pO2) in heparinized arterial and venous whole blood.
pH, pCO2 and pO2 Measurements are used in the diagnosis and treatment of life-threatening acid base disturbances.
The Stat Profile Prime Plus Analyzer System is a low cost, low maintenance analyzer for hospital laboratory and point-of-care settings. It consists of the analyzer, sensor cartridges, and thermal paper for an onboard printer. Optionally, it provides for reading of barcode labels (such as operator badges and data sheets).
The Stat Profile Prime Plus Analyzer has slots to accommodate two sensor cartridges (Primary and Auxiliary). The analyzer will determine the configuration of the system by detecting which sensor cards are installed.
As with the predicate, the Stat Profile Prime Plus Analyzer is a blood gas, co-oximetry, electrolyte, chemistry, and hematology analyzer with an enhanced test menu and multiple quality control options. Both traditional internal and external quality control is available, as well as an on-board Quality Management System (QMS), and an electronic monitoring approach that insures the analyzer is working properly at all times.
The Stat Profile Prime Plus Analyzer accepts samples from syringes and open tubes. The minimum sample size for analysis is 135 µL.
Sample collection, preparation and application to the same as for the previously cleared predicate. The end user can select which analytes are to be tested in the panel.
Here's a breakdown of the acceptance criteria and the study proving the device meets them, based on the provided FDA 510(k) summary:
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria are implicitly defined by the demonstration of "substantial equivalence" to the predicate device (Nova Stat Profile pHOx Ultra Analyzer System and K173797 - Stat Profile Prime Plus Analyzer System). The performance of the proposed device is compared to the predicate device and established CLSI guidelines for method comparison and imprecision.
| Criterion Type | Acceptance Criteria (Implicitly from CLSI/Substantial Equivalence) | Reported Device Performance (Stat Profile Prime Plus Analyzer) |
|---|---|---|
| Method Comparison (POC vs Lab) | Agreement between POC measurements and laboratory measurements for pH, pCO2, and pO2, demonstrating substantial equivalence to the predicate and clinical acceptability. | pH: N=432, Range 6.832 - 7.931, Slope 0.9930, Intercept 0.0500, r 0.9976. 95% CI of Bias: MDL (7.1-7.6) for Lower Limit (7.099, 7.595) and Upper Limit (7.102, 7.601) pO2: N=432, Range 11.5 - 555.2, Slope 1.0109, Intercept -1.5391, r 0.9989. 95% CI of Bias: MDL (40-160) for Lower Limit (38.4, 159.7) and Upper Limit (40.6, 160.7) pCO2: N=428, Range 14.0 - 199.2, Slope 0.9848, Intercept 0.9958, r 0.9963. 95% CI of Bias: MDL (20-75) for Lower Limit (19.6, 74.5) and Upper Limit (20.9, 75.2) |
| Total Imprecision | Acceptable Total SD and %CV for pH, pCO2, and pO2 across multiple levels of quality control materials and different POC personnel, according to CLSI EP5-A2T. | Level 1 (pH 7.223, pCO2 60.0 mmHg, pO2 76.5 mmHg): pH Total SD 0.008; pCO2 Total SD 3.6, %CV 5.9; pO2 Total SD 2.4, %CV 3.1 Level 2 (pH 7.428, pCO2 37.2 mmHg, pO2 112.2 mmHg): pH Total SD 0.006; pCO2 Total SD 2.3, %CV 6.1; pO2 Total SD 3.0, %CV 2.6 Level 3 (pH 7.627, pCO2 20.1 mmHg, pO2 148.9 mmHg): pH Total SD 0.008; pCO2 Total SD 1.0, %CV 4.8; pO2 Total SD 3.4, %CV 2.3 |
| Within-Run Whole Blood Precision | Acceptable Within-Run SD and %CV for pH, pCO2, and pO2 using fresh, native whole blood samples by POC operators, demonstrating consistent performance in replicate measurements. | pH: SD values ranging from 0.003 to 0.011 across 5 samples.pCO2 (mmHg): %CV values ranging from 0.70% to 1.62% across 5 samples.pO2 (mmHg): %CV values ranging from 0.80% to 4.73% across 5 samples. (Specific mean, SD, %CV provided for each of the 5 samples in Table 3) |
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size for Method Comparison:
- N = 432 for pH and pO2 (venous & arterial whole blood specimens combined)
- N = 428 for pCO2 (venous & arterial whole blood specimens combined)
- Sample Size for Total Imprecision: 40 runs (duplicate measurements each day for 20 days) for each of 3 levels of quality control materials.
- Sample Size for Within-Run Whole Blood Precision: 10 replicate measurements for each of 5 different native whole blood samples at each site.
- Data Provenance: The studies were conducted at 3 Point-of-Care (POC) sites including a Cardiothoracic Intensive Care Unit (CTICU), an Emergency Department (ED), and a Respiratory Therapy Lab (RT). The data provenance refers to real-world samples tested by clinical staff in typical POC settings. The report does not specify the country of origin, but given it's an FDA submission, it's typically understood to be within the U.S.
- Nature of Data: The method comparison used "discarded blood gas specimens" and "quality control materials" in addition to "fresh, native whole blood samples" for within-run precision. This indicates retrospective usage of discarded patient samples and prospective collection for precision studies.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
The ground truth for the method comparison study was established by "laboratory measurements" (presumably by a predicate or established laboratory analyzer). The document does not specify the number of experts or their qualifications who performed these laboratory measurements. The term "POC personnel" refers to the users of the device under test, not the ground truth establishment.
4. Adjudication Method for the Test Set
The document does not describe any specific "adjudication method" in the sense of multiple experts reviewing results and reaching a consensus. For method comparison studies of this type (quantitative measurements), the reference method (laboratory measurement) typically serves as the "ground truth" against which the new device's performance is compared, using statistical methods (slope, intercept, correlation, bias). No expert adjudication is typically involved beyond ensuring the reference method itself is properly calibrated and operated.
5. If a Multi Reader Multi Case (MRMC) Comparative Effectiveness Study was done
No, a Multi-Reader Multi-Case (MRMC) comparative effectiveness study was not explicitly done as described in the context of human readers improving with AI assistance. This device is an analyzer, not an AI-assisted diagnostic tool that interprets images or signals requiring human interpretation. The study involved different POC personnel operating the device, which is a form of multi-user testing to assess "imprecision performance" in a real-world setting, but it's not an MRMC study comparing human performance with and without AI.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
Yes, the device operates in a standalone manner to measure pH, pCO2, and pO2. The "Point-of-Care (POC) study" assessed the device's performance when operated by healthcare professionals in clinical settings, but the device itself generates the quantitative measurements automatically. The "bench testing" mentioned, performed prior to the POC study, also represents standalone performance. The values in the tables are direct measurements from the device, not interpretations aided by humans.
7. The Type of Ground Truth Used
- For Method Comparison Studies: The ground truth was established by "laboratory measurements" using presumably a reference laboratory analyzer or the predicate device.
- For Imprecision Performance: The ground truth was based on the expected values of the "quality control materials" used.
- For Within-Run Whole Blood Precision: The study evaluated the device's consistency when repeatedly measuring "fresh, native whole blood samples", where the ground truth is simply the intrinsic value of the sample, and the measurement aims to show reproducibility.
8. The Sample Size for the Training Set
This document only describes performance testing for regulatory submission (510(k)). It does not mention or provide details about a "training set" as would be relevant for machine learning algorithms. This device is a diagnostic instrument based on established electrochemical principles, not an AI/ML device that requires a training set in the conventional sense.
9. How the Ground Truth for the Training Set was Established
As no training set is described for this type of device, this question is not applicable.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food & Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" in a square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in a sans-serif font.
January 24, 2020
Nova Biomedical Corporation Rachel Gilbert Regulatory Affairs Specialist II 200 Prospect Street Waltham, MA 02454
Re: K193246
Trade/Device Name: Stat Profile Prime Plus Analyzer System Regulation Number: 21 CFR 862.1120 Regulation Name: Blood gases (PCO2, PO2) and blood pH test system Regulatory Class: Class II Product Code: CHL Dated: November 8, 2019 Received: November 25, 2019
Dear Rachel Gilbert:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's
{1}------------------------------------------------
requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Marianela Perez-Torres, Ph.D. Acting Deputy Director Division of Chemistry and Toxicology Devices OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K193246
Device Name Stat Profile Prime Plus Analyzer System
Indications for Use (Describe)
The Stat Profile Prime Plus Analyzer System is intended for use by healthcare professionals in clinical laboratory settings and for point-of-care usage for quantitative determination of pH, Partial Pressure of Carbon Dioxide (pCO2) and Partial Pressure of Oxygen (pO2) in heparinized arterial and venous whole blood.
pH, pCO2 and pO2 Measurements are used in the diagnosis and treatment of life-threatening acid base disturbances.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| X Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB number."
{3}------------------------------------------------
510(k) Summary K193246
| 510(K) Owner: | Nova Biomedical Corporation |
|---|---|
| Registration Number: | 1219029 |
| Address: | 200 Prospect St.Waltham, MA 02454 |
| Phone: | 781-894-0800 |
| Fax Number: | 784-891-4806 |
| Contact Person: | Rachel Gilbert, Regulatory Affairs Specialist I |
| Date Prepared: | November 8, 2019 |
Proprietary Name: Stat Profile Prime Plus Analyzer System
Common or Usual Name: Blood Gas Analyzer
Classification Name: Blood Gases and Blood pH System
Product Code: CHL
Predicate Device: K173797 - Stat Profile Prime Plus Analyzer System
Device Description:
The Stat Profile Prime Plus Analyzer System is a low cost, low maintenance analyzer for hospital laboratory and point-of-care settings. It consists of the analyzer, sensor cartridges, and thermal paper for an onboard printer. Optionally, it provides for reading of barcode labels (such as operator badges and data sheets).
The Stat Profile Prime Plus Analyzer has slots to accommodate two sensor cartridges (Primary and Auxiliary). The analyzer will determine the configuration of the system by detecting which sensor cards are installed.
Primary Sensor Card Port:
There are two options for the primary sensor card:
- Primary Sensor Card 1 shall enable and report the following listed analytes: . o PO2, PCO2, pH
- . Primary Sensor Card 2 shall enable and report the following listed analytes:
- o PO2, PCO2, pH
As with the predicate, the Stat Profile Prime Plus Analyzer is a blood gas, co-oximetry, electrolyte, chemistry, and hematology analyzer with an enhanced test menu and multiple quality control options. Both traditional internal and external quality control is available, as well as an on-board Quality Management System (QMS), and an electronic monitoring approach that insures the analyzer is working properly at all times.
{4}------------------------------------------------
The Stat Profile Prime Plus Analyzer accepts samples from syringes and open tubes. The minimum sample size for analysis is 135 µL.
Sample collection, preparation and application to the same as for the previously cleared predicate. The end user can select which analytes are to be tested in the panel.
Stat Profile Prime Plus Analyzer System Components:
The Stat Profile Prime Plus Analyzer System is comprised of the following components:
- . Stat Profile Prime Plus Analyzer System
- Primary Sensor Cartridge
- Auxiliary Sensor Cartridge
- Stat Profile Prime Plus Auto-Cartridge Quality Control Pack ●
- Stat Profile Prime Plus Calibrator Cartridge ●
- Stat Profile Prime Plus External Ampuled Control
- IFU/Labeling
Sample Types:
The Stat Profile Prime Plus Analyzer System accepts lithium heparinized arterial and venous whole blood.
Measured Parameters:
The Stat Profile Prime Plus Analyzer measures:
- pH
- Partial Pressure of Carbon Dioxide (pCO2)
- Partial Pressure of Oxygen (pO2)
Calculated Parameters:
The following parameters are calculated by the Prime Plus Analyzer based on results of the directly measured parameters.
- Alveolar Oxygen (A)
- . Arterial Alveolar Oxygen Tension Gradient (A-aDO2)
- Arterial Alveolar Oxygen Tension Ratio (a/A) ●
- Arterial Oxygen Content (CaO2) ●
- Arterial-Venous Oxygen Content Difference (C(a-v)O2) .
- Base Excess of Blood (BE-b)
- Base Excess of Extracellular Fluid (BE-ecf)
- . Bicarbonate level (HCO3)
- . Capillary Oxygen Content (CcO2)
- Oxygen Capacity (O₂Cap) ●
- Oxygen Content (O2Ct)
- . P50
- pH corrected to patient temperature: pH(TC)
- pCO2 corrected to patient temperature: pCO2(TC)
- pO2 corrected to patient temperature: pO2(TC)
- PO2 to FIO2 Ratio (PO2/FIO2) ●
- Qsp/Qt (Physiological Shunt)
- Respiratory Index (RI)
- Standard Bicarbonate Concentration (SBC) ●
- Total Carbon Dioxide (TCO2)
- Venous Oxygen Content (CvO2) .
{5}------------------------------------------------
Intended Use:
The Stat Profile Prime Plus Analyzer System is indicated for use by healthcare professionals in clinical laboratory settings and for point-of-care usage for quantitative determination of pH, Partial Pressure of Carbon Dioxide (pCO2), and Partial Pressure of Oxygen (pO2) in heparinized arterial and venous whole blood.
| pH, pCO2, pO2 | Measurements are used in the diagnosis and treatment of life-threatening acid base disturbances. |
|---|---|
| --------------- | -------------------------------------------------------------------------------------------------- |
Summary of the Technological Characteristics:
The Stat Profile Prime Plus Analyzer is substantially equivalent to the previously cleared for market Stat Profile Prime Plus Analyzer in intended use. It uses the same sensor technology and measurement algorithms, and the formulations of the internal and external controls and the calibration cartridge are the same for the tested parameters.
Principles of Measurement:
pH:
pH is measured using a hydrogen ion selective glass membrane. One side of the glass is in contact with a solution of constant pH. The other side is in contact with a solution of unknown pH. A change in potential develops which is proportional to the pH difference of these solutions. This change in potential is measured against a reference electrode of constant potential. The magnitude of the potential difference is a measure, then, of the pH of the unknown solution.
pCO2:
pCO2 is measured with a modified pH sensor. Carbon dioxide in the unknown solution makes contact with a gas permeable membrane mounted on a combination measuring/reference electrode. CO2 diffuses across the membrane into a thin laver of electrolyte solution in response to partial pressure difference. This solution then becomes equilibrated with the external gas pressure. CO2 in the solution becomes hydrated producing carbonic acid, which results in a change in hydrogen ion activity.
pO2:
pQ2 is measured amperometrically by the generation of a current at the sensor surface. As oxygen diffuses through a gas permeable membrane, the oxygen molecules are reduced at the cathode, consuming 4 electrons for every molecule of oxygen reduced. This flow of electrons is then measured by the sensor and is directly proportional to the partial pressure of oxygen.
Summary of Performance Testing:
Bench testing was previously completed and summarized in K173797 to show that the Stat Profile Prime Plus Analyzer demonstrates substantial equivalence to the predicate submission.
The bench testing included:
- . Method Comparison Studies
- Precision/Reproducibility - Within Run and Run to Run Studies
- Linearity Testing ●
- Specificity/Interference Testing ●
The results of that testing confirmed that the performance of the Stat Profile Prime Plus Analyzer System is substantially equivalent to that of the Nova Stat Profile pHOx Ultra Analyzer System (predicate device).
{6}------------------------------------------------
Summary of Point-of-Care Testing:
A Point-of-Care (POC) study was conducted to demonstrate that the Stat Profile Prime Plus Analyzer demonstrates substantial equivalence to the predicate submission. The testing compared results obtained by trained Healthcare Professionals to results obtained by POC personnel on the same specimens using the same analyzer. The Stat Profile Prime Plus Analyzer was evaluated by point-of-care (POC) personnel in 3 POC sites including a Cardiothoracic Intensive Care Unit (CTICU), an Emergency Department (ED) and a Respiratory Therapy Lab (RT). A total of 61 Respiratory Care, 12 Nursing, and 1 Exercise Physiology POC personnel participated from the 3 POC settings over the course of the study. The personnel represent trained, qualified staff found in typical POC sites where blood gas analyzers are utilized. All testing was performed using quality control materials or discarded blood gas specimens.
Method Comparison studies on venous and arterial whole blood specimens were conducted using methods described in CLSI "Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline - Second Edition", CLSI EP9-A2. Combined method comparison data from all 3 POC settings is summarized in Table 1.
| 95% ConfidenceInterval of Bias | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Analyte | N | # alteredsamples | range | Slope | Intercept | r | MDL | LowerLimit | UpperLimit |
| pH | 432 | 18 | 6.832 - 7.931 | 0.9930 | 0.0500 | 0.9976 | 7.17.6 | 7.099 | 7.102 |
| 7.595 | 7.601 | ||||||||
| pO2 | 432 | 18 | 11.5 - 555.2 | 1.0109 | -1.5391 | 0.9989 | 40160 | 38.4 | 40.6 |
| 159.7 | 160.7 | ||||||||
| pCO2 | 428 | 14 | 14.0 - 199.2 | 0.9848 | 0.9958 | 0.9963 | 2075 | 19.6 | 20.9 |
| 74.5 | 75.2 |
Table 1: Venous & Arterial Whole Blood Method Comparison Results - POC vs Lab (ED, RT and CTICU)
Total Imprecision Performance:
The estimates for total impression were obtained from different POC personnel running 3 levels of Stat Profile Prime Plus Quality Control Materials in duplicate each day for a total of 20 runs on 3 Stat Profile Prime Plus analyzers. The protocol was based upon methods described in CLSI Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline-Second Edition, CLSI EP5-A2T. The total imprecision data from one representative POC site is shown in Table 2 and is representative of the expected total imprecision performance obtainable by POC personnel using the Stat Profile Prime Plus analyzer using external quality control materials.
| Blood Gas Quality Control, Level 1 | ||||||
|---|---|---|---|---|---|---|
| PooledMean | N | Within RunSD | Within Run%CV | Total SD | Total%CV | |
| pH | 7.223 | 40 | 0.004 | N/A | 0.008 | N/A |
| pCO2 (mmHg) | 60.0 | 40 | 1.6 | 2.6 | 3.6 | 5.9 |
| pO2 (mmHg) | 76.5 | 40 | 1.3 | 1.6 | 2.4 | 3.1 |
Table 2: Total Imprecision From ED Site
{7}------------------------------------------------
| Blood Gas Quality Control, Level 2 | ||||||
|---|---|---|---|---|---|---|
| pH | 7.428 | 40 | 0.003 | N/A | 0.006 | N/A |
| pCO2 (mmHg) | 37.2 | 40 | 1.1 | 3.0 | 2.3 | 6.1 |
| pO2 (mmHg) | 112.2 | 40 | 1.6 | 1.4 | 3.0 | 2.6 |
| Blood Gas Quality Control, Level 3 | ||||||
| pH | 7.627 | 40 | 0.006 | N/A | 0.008 | N/A |
| pCO2 (mmHg) | 20.1 | 40 | 0.6 | 3.1 | 1.0 | 4.8 |
| pO2 (mmHg) | 148.9 | 40 | 1.6 | 1.1 | 3.4 | 2.3 |
Within-Run Whole Blood Precision:
Whole blood with-run precision of the Stat Profile Prime Plus Analyzer System in the hands of point-ofcare operators was assessed by two (2) point-of-care operators at each of the three (3) POC sites for a total of six (6) point-of-care operators across the 3 testing locations. Each precision run consisted of ten (10) replicate measurements using fresh, native whole blood samples. A total of five (5) different native samples were evaluated at each site. Each whole blood specimen was maintained in a syringe. The POC operator performed all sample analysis steps including sample analysis, removal of resultant air bubble(s) from the syringe, recapping of the syringe and mixing prior to the next sample analysis. The whole blood within-run precision data from one representative POC site is shown in Table 3 and is representative of the expected within-run precision obtainable by POC personnel using the Stat Profile Prime Plus analyzer using whole blood samples.
| Mean | SD | %CV | 95% CI | ||
|---|---|---|---|---|---|
| Sample 1 | |||||
| pH | 7.287 | 0.011 | N/A | 7.265 - 7.308 | |
| pCO2 (mmHg) | 50.6 | 0.82 | 1.62 | 49.0 - 52.2 | |
| pO2 (mmHg) | 57.9 | 0.46 | 0.80 | 56.9 - 58.8 | |
| Sample 2 | |||||
| pH | 7.282 | 0.003 | N/A | 7.277 - 7.288 | |
| pCO2 (mmHg) | 19.7 | 0.26 | 1.31 | 19.2 - 20.2 | |
| pO2 (mmHg) | 66.7 | 1.34 | 2.01 | 64.0 - 69.3 | |
| Sample 3 | |||||
| pH | 7.405 | 0.005 | N/A | 7.395 - 7.415 | |
| pCO2 (mmHg) | 31.0 | 0.22 | 0.70 | 3.05 - 31.4 | |
| pO2 (mmHg) | 91.4 | 1.72 | 1.88 | 87.9 - 94.8 | |
| Sample 4 | |||||
| pH | 7.347 | 0.006 | N/A | 7.336 - 7.358 | |
| pCO2 (mmHg) | 38.2 | 0.33 | 0.86 | 37.6 - 38.9 | |
| pO2 (mmHg) | 643.0 | 30.44 | 4.73 | 582.1 - 703.9 | |
| Sample 5 | |||||
| pH | 7.396 | 0.003 | N/A | 7.389 - 7.402 | |
| pCO2 (mmHg) | 34.5 | 0.39 | 1.14 | 33.7 - 35.3 | |
| pO2 (mmHg) | 84.0 | 1.62 | 1.93 | 80.8 - 87.2 |
Table 3: Within Run Precision with Whole Blood Samples (n=10) – ED
{8}------------------------------------------------
Conclusion:
The results of the POC clinical performance verification testing confirmed that the Stat Profile Prime Plus Analyzer is substantially equivalent to the predicate Stat Profile Prime Plus Analyzer System (K173797).
| Characteristic | Predicate: | Proposed: |
|---|---|---|
| Indication For Use | The Stat Profile Prime Plus Analyzer Systemis indicated for use by healthcareprofessionals in clinical laboratory settings forquantitative determination of pH, PartialPressure of Carbon Dioxide (pCO2), andPartial Pressure of Oxygen (pO2) inheparinized arterial and venous whole blood. | The Stat Profile Prime Plus Analyzer Systemis indicated for use by healthcareprofessionals in clinical laboratory settingsand for point-of care usage for quantitativedetermination of pH, Partial Pressure ofCarbon Dioxide (pCO2), and Partial Pressureof Oxygen (pO2) in heparinized arterial andvenous whole blood. |
| Acceptable Samples | ||
| Sample Types | Lithium heparin whole blood from syringesand open tubes | Same |
| Sample Volumes | 135µL | Same |
| Measurement Range | ||
| pH | 6.500 to 8.000 (pH units) | Same |
| PCO2 | 3.0 to 200.0 mmHg | Same |
| PO2 | 5.0 to 765 mmHg | Same |
| Principles ofMeasurement | ||
| pH | Hydrogen ion-selective glass sensor | Same |
| PCO2 | Severinghaus-type sensor | Same |
| PO2 | Polarographic Clark-type sensor | Same |
| Touch Screen | 10.1" WXGA 1280 x 800 color touch screen | Same |
| Menu | Fully configurable test menu based onavailable sensors | Same |
| Bar Code Scanner | Internal Integrated 1D/2D | Same |
| Printer | 2" Roll, Thermal Transfer | Same |
| Pump | Peristaltic Pump w/ Pressure Plate, TPETubing (Pharmed BPT) | Same |
| Analog Board | Precision low level analog front end w/amperometric and potentiometric amplifiers,air detector circuitry and temperature controlcircuitry | Same |
Table 4: Comparison of Predicate and Proposed Devices
§ 862.1120 Blood gases (P
CO2 , PO2 ) and blood pH test system.(a)
Identification. A blood gases (PCO2 , PO2 ) and blood pH test system is a device intended to measure certain gases in blood, serum, plasma or pH of blood, serum, and plasma. Measurements of blood gases (PCO2 , PO2 ) and blood pH are used in the diagnosis and treatment of life-threatening acid-base disturbances.(b)
Classification. Class II.